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Aim: Although diabetic retinopathy (DR) screening is a basic component of diabetes care,
uptake of screening programs is less than optimal. Because attendance rates and reasons for
non-attendance in an unselected diabetes population are unknown, this study examines
incentives and barriers to attend DR-screening.
Method: Four focus groups provided patient-related themes concerning individual decision-
making regarding attendance at DR-screening. A questionnaire measuring attendance rates
and the influence of several factors was sent to 3236 diabetes patients (>18 years) in 20
Dutch general practices, of which 2363 (73%) responded.
Results: In the past 3 years, 81% of the patients had attended DR-screening. Patients not
attending had lower levels of education, a more recent diagnosis of diabetes, and less
frequently used insulin. There was no difference in DM types 1 and 2 patients regarding
attendance. Patients attending more often visited health-care providers. Patients reported
‘knowledge of detrimental effects of DR on visual acuity’, ‘sense of duty’ and ‘fear of
impaired vision’ as main incentives. The main barrier was the absence of a recommendation
by the health-care provider.
Conclusion: Knowledge about detrimental effects of DR on visual acuity and recommenda-
tion by health-care providers are important, possibly modifiable, factors in the attendance
to DR screening.
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Diabetic retinopathy (DR) is an important cause of visual
impairment and blindness among adults aged 20–74 years in
the USA and the UK [1,2]. About 50–73% of those with visual
impairment or blindness as a result of DR can be prevented by
early detection and treatment of risk factors, and by
photocoagulation [3,4]. Therefore, the International Diabetes
Federation guidelines recommend early detection of DR by* Corresponding author at: Postal zone V-0-P, Leiden University M
PO Box 9600, 2300 RC Leiden, The Netherlands. Tel.: +31 71 526844
E-mail address: J.W.Blom@lumc.nl (J.W. Blom).
0168-8227 # 2011 Elsevier Ireland Ltd. 
doi:10.1016/j.diabres.2011.11.003
Open access under the Elsevier OA licensemeans of DR screening [5]. Prevention of visual loss has
improved considerably during the last decade, especially in
northern Europe [6]. However, patient compliance with DR
screening is not optimal, as shown by attendance rates
ranging from 32 to 85% [8–15].
To increase DR screening attendance, insight into incen-
tives and barriers to retinopathy screening is necessary.
Because earlier studies on this topic have a qualitative design,
no reliable analyses could be made. However, longer diabetes
duration, older age and diabetes-related visual problems areedical Center, Department of Public Health and Primary Care,
4; fax: +31 71 5268259.
.
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financial barriers are also often reported [7,13,16–18]. Never-
theless, the main barrier for compliance was the patient’s
belief that they do not have DR [11,19]. Other factors were
embarrassment about poor glycemic control and fear of
ophthalmological treatment [16,20]. Many conclude that
patients’ lack of awareness (due to lack of education/
information) is the main obstacle to attend a screening
program [7,10,12,13,15,16,20].
In view of the major investments in screening and
treatment programs, developing interventions to reduce
non-compliance should be a priority [6].
The Dutch guidelines for screening for DR recommend a
screening interval of maximally 2 years [21]. To evaluate
compliance with retinopathy screening in the Netherlands,
the present study assesses current attendance rates of DR
screening among patients with diabetes mellitus in Dutch
primary care. Sociodemographic and clinical factors related to
(non-)attendance, as well as the patient’s incentives and
barriers to screening, are examined.
2. Material and methods
2.1. Development of the questionnaire
In the absence of a suitable tool to evaluate which incentives/
barriers play a role in attending DR screening, we used a
qualitative approach to develop such a questionnaire [22].
First, the literature was searched for reports on individual
incentives/barriers to attend DR screening (e.g., attitude and
behavior, incentives and barriers to retinopathy screening,
knowledge of visual impairment as a result of DR, and the
necessity of screening to prevent this, former experiences in
screening, and practical inconveniences). Then, interviews
were held with 6 general practitioners (GPs) and with 4 patients
with diabetes mellitus to reveal more incentives/barriers that
are important to these specialists/patients. Interviews were
recorded and transcribed verbatim. Analysis of the interviews
was aimed at finding all possible issues important for attending/
not attending DR screening. Issues were clustered into themes
to be used in focus group interviews.
Four focus group meetings were held (in 2006) to evaluate
which factors play a role in attending DR screening. All
participants were invited by their GP. Informed consent was
completed. All meetings were conducted by a professional
moderator using a predefined list of topics. The groups were
comprised of a mix of attendees and non-attendees in DR
screening programs. Separate meetings were held with urban
and rural patients (6 miles/10 km from the hospital where
the DR screening was performed). A third focus group
consisted of active members of the Dutch Diabetes Associa-
tion. The fourth focus group consisted of people with a non-
western-European cultural background (of Moroccan origin).
In this latter group, additional questions were asked about the
influence of language barriers and the possible role of different
cultural backgrounds.
All group interviews were recorded and transcribed
verbatim. All incentives and barriers mentioned in the verbatim
reports were scored independently by two researchers (KvE,YG). Findings derived from the literature, from the individual
interviews, and from the focus group interviews were then
incorporated into a questionnaire (Appendix).
2.2. Quantitative study
All participants with diabetes mellitus (types 1 and 2) (ICPC
code T90) aged 18 years and over, registered in 20 Dutch
general practices, received a printed questionnaire in 2008.
Three weeks later, a reminder was sent to non-responding
participants containing a response card with two questions:
‘Did you attend DR screening in the last 3 years?’ and ‘What
was your main reason for doing so?’
A non-response analysis was performed in one of the
participating health centers. Of the 160 patients in this center,
33 had not responded. This latter group were telephoned by
the nurse practitioner and invited to respond to the above-
mentioned questions.
The questionnaire had 3 parts:
Part I: Patient’s sociodemographic and clinical character-
istics, including age, sex, self-reported height/weight, educa-
tion level, origin (Western-European vs. non-Western
European), type of diabetes, age of diagnosis, self-reported
HbA1c, diabetes medication(s), and the location of diabetes
care (i.e., general practice or elsewhere).
Part II: Attendance at DR screening: ‘attendees’ were
defined as patients who underwent DR screening within the
last 3 years, ‘non-attendees’ were defined as diabetes patients
who had not attended DR screening in the last 3 years. The 3-
year period ensures that these patients were ‘real’ non-
attendees taking into account the Dutch guideline of ‘‘mini-
mally one DR screening within two years’’ [21].
Part III: Presence of potential incentives and barriers to
retinopathy screening. The questions covered all potential
incentives/barriers from the schedules derived from the focus
group interviews. All questions in Part III were phrased
differently in order to be appropriate for attendees and non-
attendees. Table 1 presents an example of two typical
questions.
3. Analysis
Data were analyzed using SPSS statistical software (version
12.0.1). Descriptive statistics were used to assess the differ-
ence in prevalence of screening attendance among the
patients. To analyze differences in sociodemographic and
clinical characteristics between attendees and non-attendees,
we used chi-square tests for categorical data and t-tests for
continuous data. Chi-square analyses and odds ratios were
applied to compare incentives and barriers between attendees
and non-attendees.
4. Results
4.1. Qualitative study
The first focus group was comprised of 5 patients (2 men, 3
women, accompanied by 2 interpreters) born in Morocco, the
Table 1 – Example of questions in the questionnaires.
Subject Question in the questionnaire
Recommendation by care provider A. Has your GP, internist or GP nurse ever told you that your eyes needed
checking because you have diabetes? Yes/No/I do not know
Is this advice a reason to have your eyes checked? Yes/No/I do not know
If your GP or internist had not told you that you need your eyes checked
because of your diabetes, would you still have had your eyes checked? Yes/No
B. Has your GP, internist or GP nurse ever told you that your eyes needed
checking because you have diabetes? Yes/No/I do not know
If no, is this a reason not to have your eyes checked? Yes/No/I do not know
If your GP or internist had told you that you need to have your eyes checked
because of your diabetes, would you have had your eyes checked? Yes/No
Awareness of possibility to treat DR A. Can damage to the eyes caused by diabetes be treated? Yes/No/I do not know
If you answered yes: is this a reason to get your eyes checked? Yes/No
If you thought that damage to the eyes caused by diabetes could not be treated,
would you still have had your eyes checked? Yes/No/I do not know
B. Can damage to the eyes caused by diabetes be treated? Yes/No/I do not know
If you answered no: is this a reason not to get your eyes checked? Yes/No
If you thought that damage to the eyes caused by diabetes could be treated,
would you have had your eyes checked? Yes/No/I do not know
A, the group who had a DR screening test in the last three years; B, the group who have not had a DR screening test in the last three years.
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 9 6 ( 2 0 1 2 ) 1 0 – 1 612second group of 4 men and 4 women (active members of the
Dutch Diabetes Foundation), the third group of 9 urban
patients (4 men and 5 women), and the fourth group was
comprised of 8 rural patients (3 men and 5 women).
Tables 3 and 4 present the potential incentives and barriers
derived from the interviews and the focus groups.
4.2. Quantitative study
The questionnaire was sent to 3236 patients with diabetes
mellitus. Of these potential participants, 1891 patients (58.4%)
filled in the questionnaire and 475 (14.7%) returned the
response card stating attendance (total response for response
card 73.1%). For the non-response analysis, 100% of the non
responding patients of a large group practice were reached by
telephone (Fig. 1).
In total, 1917 patients (81.0%) had undergone eye screening
in the last 3 years and 449 (19.0%) had not been screened
during that period. Screening attendance rates between the
general practices ranged from 58.8 to 91.8%. Non-response (to
the questionnaire) analysis (n = 33) showed a screening
attendance of 78.1% among non-responders which was
similar to the attendance among responders in this practice
(81.0%).
Table 2 shows that attendees more often had a higher
education than non-attendees. Patients with diabetes for 10
years or more and those using insulin were more often
frequent attendees. Attendees were more frequently treated
by an internist.
In most cases, eyes were examined by means of fundo-
scopy (74.2%), whereas in 18.1% the eyes were screened by
means of fundus photography and 7.7% of the patients did not
remember which screening method was used. Examination in
mydriasis was reported by 85% of the patients screened by
fundus photography.Incentives that occurred less frequently among non-
attendees were: eye screening recommendation made by
the care provider, awareness of the detrimental effects of
diabetic retinopathy on visual acuity, feeling obliged to attend
retinopathy screening, and fear of impaired vision (Table 3).
Impaired vision or eye complaints occurred more frequently
among non-attendees.
Barriers occurring more frequently among non-attendees
were: no eye screening recommendation made by their care
provider, lack of awareness of the detrimental effects of DR on
visual acuity, screening was not thought to be useful at the
patients’ age (patients aged 70 years), no confidence in
doctors, no interest or no time to attend, waiting time over
30 min, requiring an accompanying person, and physical
disability (Table 4). Fear of the results of eye screening
occurred less frequently among non-attendees.
5. Discussion
5.1. Summary of main findings
In these 20 Dutch general practices, 81% of the patients with
diabetes mellitus (types 1 and 2) attended retinopathy
screening. Non-attendees had lower levels of education,
shorter duration of diabetes and were less likely to use
insulin, or be checked by an internist. The main incentive to
attend eye screening is knowledge about the detrimental
effects of DR on visual acuity. The main barrier to compliance
is the absence of a recommendation by the general practition-
er, internist or practice nurse.
Surprisingly, although it is tempting to believe that
participants with DM type 2 know more about complications
and have a longer duration of disease, we found no difference
in attendance between participants with DM type 1 and DM
Questionnaire   
(n=3236) 
Responders  
(n=1891) 
Non -res pon der s 
(n=1345) 
Reminder  
Responders 
(n=475) 
Non -res pon ders 
(n=870) 
Non -resp onse ana lysis  
in  1 health  center 
(n=35) 
20 gener al pr actices;  
patients  with  diabetes 
mellitus  ty pe 1/2,  ag e ≥18 
years 
(n=3241) 
2 pat ients died;  
3 pat ients withou t 
diabete s mellitu s
Fig. 1 – Flowchart showing participation in the present study.
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providers (lower frequency of no care, lower frequency of
GP only, higher frequency of internal medicine). Earlier
interventions have shown that better access to health care
increases DR screening attendance [23]. Attendees more often
expressed a fear of complications as an incentive for
screening, and more often feel reassured by the results of
the screening. In an earlier qualitative study, patients
indicated knowledge about DR affecting the eye but not about
DR leading to blindness [12]. More detailed information about
complications might help to increase attendance. Although a
sense of duty stimulated attendance, guilt related to poor
control has been shown to deter patients from attending [12],
implying that a positive feedback about attendance could be
important.5.2. Strengths and limitations of the study, comparison
with existing literature
This study has several strengths. First, the study population is
large, representative of the diabetes population in the
Netherlands [24], and with a high response rate. Although
the attendance rate might be an overestimation due to 26.9%
non-responders, non-response analysis showed no differ-
ences in screening attendance between responders and non-
responders. An attendance rate of 81% is relatively low
considering the broad inclusion criteria, but is still probably
higher than that in similar studies which reported annual and
biannual rates [12,14], except for one study from Scandinavia
(98% biannually) [15]. Diabetes care in the Netherlands has
improved recently, stimulated by broadly accepted guidelines,
Table 2 – Sociodemographic and clinical characteristics of attendees of diabetic retinopathy (DR) screening, and non-
attendees of DR screening within the last 3 years.
Attendees of DR
screening (n = 1589)
Non-attendees of DR
screening (n = 302)
p-Value
Sex
Male 49.3 49.4
Female 50.7 50.6 0.980
Age (years)
<50 12.5 16.1
50–60 26.6 32.2
61–70 31.3 20.4
71–80 20.7 17.3
>80 8.9 14.1 0.459
Education
High (age > 12 years) 91.6 85.4
Low (age  12 years) 8.4 14.6 0.002
Origin
Western origin 82.7 79.2
Non-western origin 17.3 20.8 0.176
Type of diabetes
Type 1 11.5 8.9
Type 2 88.5 91.1 0.314
Duration of diabetes
Recent (10 years) 55.3 66.8
Not recent (>10 years) 44.7 33.2 <0.001
Medication
No medication 14.8 36.7
Oral medication 56.2 54.6
Insulin 14.5 4.8
Oral medication + insulin 14.5 4.0 <0.001
Organisation of patient’s general practitioner (GP)
Single-handed 75.1 77.5
Practice nurse/health center 24.9 22.5 0.373
Diabetes care
No care 3.3 13.3
GP 67.5 76.8
Internal medicine (with or without GP) 29.2 10.0 <0.001
Body mass index (mean  SD) 28.6  5.0 28.7  5.6 0.360
HbA1c (mean  SD) 6.8  1.0 6.9  1.6 0.846
All data are self-reported and presented as %, unless otherwise stated.
Table 3 – Individual incentives to diabetic retinopathy (DR) screening.
Attendees of DR
screening (n = 1589)
Non-attendees of DR
screening (n = 302)
Odds ratio (95% CI)
Knowledge and instructions
Recommendation by care provider 99.4 34.5 341 (164–715)
Knowledge of effects of DR on vision 96.8 90.1 3.3 (2.0–5.5)
Acquaintances with impaired vision due to DR 28.8 22.2 1.4 (1.0–2.1)
Awareness of possibility to treat DR 84.6 77.4 1.6 (0.9–3.0)
Recommendation by friends or family 17.6 20.8 0.8 (0.6–1.1)
Medical considerations
Impaired vision or eye complaints 30.2 37.3 0.7 (0.6–0.9)
Sense of duty
Feeling obliged to attend 98.7 91.1 7.7 (4.2–14.3)
Fear
Fear of impaired visual acuity 60.9 44.4 1.9 (1.5–2.5)
Reassurance by favorable screening results 97.3 95.0 1.9 (1.0–3.6)
Fear that one’s own eyes have been damaged 13.5 8.6 1.7 (0.9–3.0)
Data are presented as %.
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driven prompting. However, the high compliance rate in the
present study could be due to the broad definition of
‘attendance’ (i.e., eye screening in the last 3 years).The questions (about similar concepts) were phrased
differently for attendees and non-attendees (Table 1) in order
to avoid information bias by participants having to give
answers to hypothetical situations.
Table 4 – Individual barriers to diabetic retinopathy (DR) screening.
Factors Attendees of DR
screening (n = 1589)
Non-attendees of DR
screening (n = 302)
Odds ratio (95% CI)
Knowledge and instructions
No recommendation by care provider 0.6 65.5 0.003 (0.001–0.006)
No awareness of effects of DR on vision 3.2 9.9 0.3 (0.2–0.5)
Belief that one’s own eyes are not damaged 86.5 91.4 0.6 (0.3–1.1)
Medical considerations
Not useful at patient’s age (i.e., >70 years only) 1.5 12.9 0.11 (0.04–0.29)
No confidence in doctors 1.4 4.2 0.3 (0.2–0.7)
No impaired vision or eye complaints 69.8 62.7 1.4 (1.1–1.8)
No gain in information from screening results 17.7 15.1 1.2 (0.9–1.7)
Fear
Fear of results of eye screening 46.7 32.1 1.9 (1.4–2.4)
Fear of eye injury during screening 11.2 8.4 1.4 (0.9–2.2)
Practical inconveniences
Not interested in attendance 11.1 19.9 0.5 (0.4–0.7)
No time to attend 7.1 14.4 0.5 (0.3–0.7)
Waiting time over 30 min 34.1 50.8 0.5 (0.4–0.7)
Requiring an accompanying person 46.0 57.0 0.6 (0.5–0.8)
Physical disability 25.1 30.9 0.7 (0.6–1.0)
Laborious to make an appointment 28.5 33.0 0.8 (0.6–1.1)
Living more than 6 miles (10 km) from
the screening location
49.6 44.4 1.2 (0.9–1.6)
Other
Religious considerations 55.2 57.2 0.9 (0.7–1.2)
Data are presented as %.
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draw conclusions about whether or not participants who
indicated barriers will subsequently attend screening. The
present study focuses only on the patients’ current opinion.
5.3. Implications for future research or clinical practice
The main areas for improvement are concerned with
knowledge, awareness and instruction, implying that both
the main incentives and barriers are related to these topics.
Moreover, all these are modifiable factors. Some non-
attendees may be inclined to externalize the reasons for their
non-compliance, ignoring their caregivers’ efforts to stimulate
them to attend. However, apart from the waiting time,
practical inconveniences were not highly rated barriers (Table
4). Moreover, the large range in screening attendance rates
between the practices (59–92%) indicates that practice
organisation can probably modify attendance. A systematic
review reported that increasing patient awareness of DR and
improving provider/practice performance can increase
screening attendance [23]. Thus, GPs, internists and practice
nurses should focus on information, recommendation and
follow-up to encourage attendance in DR screening. However,
attendance is also influenced by environmental, cultural and
personal factors (e.g., a lack of trust in doctors) which cannot
be unravelled via a questionnaire. The barriers towards
attendance may also lie within these areas. For those in
high-risk groups (such as underserved inner-city areas, and
populations using different languages or with financial
constraints) not only is active education and encouragement
necessary but also facilitation of DR screening by the provision
of inexpensive surveys by appropriately trained technicians.Collaboration with community-based organisations in order
to reach high-risk groups could be an effective way to increase
DR screening [23].
6. Conclusion
Apart from the more personal views on incentives and
barriers, effective areas to increase attendance seem to be
related to knowledge, awareness and instruction. Thus, even
in this population with high attendance, the key to increasing
attendance may lie with health professionals raising aware-
ness about the benefits of screening. The practice organisa-
tions can play a role by identifying and actively prompting
non-attendees to undergo DR screening.
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